NETrolyze™ is an investigational therapy designed to target a key component of the innate immune response: neutrophil extracellular traps (NETs). These web-like structures, while originally intended to fight infection, have been implicated in driving tumor progression. Research shows that NETs can create a self-perpetuating cycle that fuels tumor growth, suppresses anti-tumor immunity, and reduces the effectiveness of standard treatments like checkpoint inhibitors and chemotherapy.

NETrolyze is engineered to disrupt this cycle by selectively degrading NETs locally within the primary tumor microenvironment—without compromising the broader immune system.

Our lead indication is triple-negative breast cancer (TNBC), an aggressive solid tumor with limited treatment options. Preclinical data suggest that NETrolyze may help delay or prevent metastasis, improve responsiveness to immunotherapy, and ultimately enhance long-term outcomes for patients.

We’re not just studying NETs — we’re building the fundamental tools to outsmart it. Our executive leadership team blends discovery with execution to bring NETrolyze and other investigational NET-targeted therapies to the clinic.